Overview Dividends

(ACAD) ACADIA Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0042251084

Parkinsons Psychosis Drug, Rett Syndrome Treatment, Schizophrenia Candidate, Alzheimers Psychosis Drug, Essential Tremor Candidate

ACAD EPS (Earnings per Share)

EPS Growth (3Y CAGR): 81.76%
EPS Trend (3Y Correlation): 69.4%

ACAD Revenue

Revenue Growth (3Y CAGR): 29.63%
Revenue Trend (3Y Correlation): 88.2%

Risk via 10d forecast
Volatility	47.8%
Value at Risk 5%th	64.6%

Reward
Sharpe Ratio	0.71
Alpha Jensen	24.64

Character
Hurst Exponent	0.365
Beta	0.682

Drawdowns 3y
Max DD	57.87%
Mean DD	31.00%

Description: ACAD ACADIA Pharmaceuticals November 09, 2025

ACADIA Pharmaceuticals (NASDAQ:ACAD) is a U.S.-based biopharma focused on central nervous system (CNS) disorders and rare diseases, commercializing NUPLAZID (pimavanserin) for Parkinson’s disease psychosis and developing a pipeline of novel agents across schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, essential tremor, treatment-resistant depression, Rett syndrome, and Fragile X.

NUPLAZID generated $215 million in 2023 revenue, representing roughly 70 % of ACAD’s total sales, and the drug benefits from a 10-year orphan exclusivity period that underpins a stable cash flow in a niche market.

The pipeline’s most advanced candidates include pimavanserin for negative-symptom schizophrenia (Phase III completed), ACP-101 for hyperphagia in Prader-Willi syndrome (Phase III completed), and ACP-204 for Alzheimer’s disease and Lewy-body dementia psychosis (Phase II completed); collectively these address indications with an estimated addressable market of >$8 billion in the U.S. alone.

As of the latest 10-Q, ACAD held $450 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates; R&D expense averaged $120 million annually, reflecting a heavy investment in late-stage trials.

The CNS biotech sector is being propelled by an aging population, rising prevalence of neurodegenerative disorders, and favorable regulatory pathways for rare-disease therapies, all of which create a supportive macro environment for ACAD’s focus areas.

For a deeper, data-driven assessment of ACAD’s valuation and risk profile, you may find the analytics on ValueRay worth exploring.

ACAD Stock Overview

Market Cap in USD	3,818m
Sub-Industry	Biotechnology
IPO / Inception	2004-05-27
Return 12m vs S&P 500	16.1%
Analyst Rating	3.95 of 5

ACAD Dividends

Currently no dividends paid

ACAD Growth Ratios

CAGR	16.85%
CAGR/Max DD Calmar Ratio	0.29
CAGR/Mean DD Pain Ratio	0.54
Current Volume	2390.6k
Average Volume	1660.5k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (261.2m TTM) > 0 and > 6% of Revenue (6% = 62.8m TTM)

FCFTA 0.15 (>2.0%) and ΔFCFTA -5.88pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 68.74% (prev 47.82%; Δ 20.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.15 (>3.0%) and CFO 198.9m <= Net Income 261.2m (YES >=105%, WARN >=100%)

Net Debt (-215.0m) to EBITDA (105.5m) ratio: -2.04 <= 3.0 (WARN <= 3.5)

Current Ratio 3.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (170.7m) change vs 12m ago 2.69% (target <= -2.0% for YES)

Gross Margin 91.92% (prev 91.61%; Δ 0.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 90.75% (prev 95.12%; Δ -4.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -0.27 (EBITDA TTM 105.5m / Interest Expense TTM -215.0m) >= 6 (WARN >= 3)

Altman Z'' -6.52

(A) 0.54 = (Total Current Assets 1.08b - Total Current Liabilities 356.6m) / Total Assets 1.33b

(B) -1.57 = Retained Earnings (Balance) -2.09b / Total Assets 1.33b

warn (B) unusual magnitude: -1.57 — check mapping/units

(D) -5.04 = Book Value of Equity -2.09b / Total Liabilities 413.5m

Total Rating: -6.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 86.09

1. Piotroski 3.0pt = -2.0

2. FCF Yield 6.56% = 3.28

3. FCF Margin 18.89% = 4.72

4. Debt/Equity 0.05 = 2.50

5. Debt/Ebitda -2.04 = 2.50

6. ROIC - WACC (= 37.69)% = 12.50

7. RoE 32.27% = 2.50

8. Rev. Trend 88.17% = 6.61

9. EPS Trend 69.42% = 3.47

What is the price of ACAD shares?

As of November 13, 2025, the stock is trading at USD 24.13 with a total of 2,390,569 shares traded.
Over the past week, the price has changed by +8.06%, over one month by +20.29%, over three months by -5.19% and over the past year by +34.58%.

Is ACADIA Pharmaceuticals a good stock to buy?

Yes, based on ValueRay´s Fundamental Analyses, ACADIA Pharmaceuticals (NASDAQ:ACAD) is currently (November 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 86.09 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ACAD is around 22.00 USD . This means that ACAD is currently overvalued and has a potential downside of -8.83%.

Is ACAD a buy, sell or hold?

ACADIA Pharmaceuticals has received a consensus analysts rating of 3.95. Therefore, it is recommended to buy ACAD.

Strong Buy: 7
Buy: 6
Hold: 6
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the ACAD price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	29.1	20.4%
Analysts Target Price	29.1	20.4%
ValueRay Target Price	24.5	1.6%

ACAD Fundamental Data Overview November 10, 2025

Market Cap USD = 3.82b (3.82b USD * 1.0 USD.USD)
P/E Trailing = 14.5613
P/E Forward = 20.7469
P/S = 3.6466
P/B = 4.3861
P/EG = -0.42
Beta = 0.682
Revenue TTM = 1.05b USD
EBIT TTM = 58.7m USD
EBITDA TTM = 105.5m USD
Long Term Debt = 52.0m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 19.9m USD (from shortTermDebt, last fiscal year)
Debt = 43.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -215.0m USD (from netDebt column, last quarter)
Enterprise Value = 3.01b USD (3.82b + Debt 43.0m - CCE 847.0m)
Interest Coverage Ratio = -0.27 (Ebit TTM 58.7m / Interest Expense TTM -215.0m)
FCF Yield = 6.56% (FCF TTM 197.8m / Enterprise Value 3.01b)
FCF Margin = 18.89% (FCF TTM 197.8m / Revenue TTM 1.05b)
Net Margin = 24.94% (Net Income TTM 261.2m / Revenue TTM 1.05b)
Gross Margin = 91.92% ((Revenue TTM 1.05b - Cost of Revenue TTM 84.6m) / Revenue TTM)
Gross Margin QoQ = 92.23% (prev 92.16%)
Tobins Q-Ratio = 2.27 (Enterprise Value 3.01b / Total Assets 1.33b)
Interest Expense / Debt = 21.08% (Interest Expense 9.07m / Debt 43.0m)
Taxrate = -60.96% (out of range, set to none) (-27.2m / 44.6m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 3.02 (Total Current Assets 1.08b / Total Current Liabilities 356.6m)
Debt / Equity = 0.05 (Debt 43.0m / totalStockholderEquity, last quarter 917.3m)
Debt / EBITDA = -2.04 (Net Debt -215.0m / EBITDA 105.5m)
Debt / FCF = -1.09 (Net Debt -215.0m / FCF TTM 197.8m)
Total Stockholder Equity = 809.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 19.63% (Net Income 261.2m / Total Assets 1.33b)
RoE = 32.27% (Net Income TTM 261.2m / Total Stockholder Equity 809.4m)
RoCE = 6.81% (EBIT 58.7m / Capital Employed (Equity 809.4m + L.T.Debt 52.0m))
RoIC = 46.12% (EBIT 58.7m / (Assets 1.33b - Curr.Liab 356.6m - Cash 847.0m))
WACC = 8.43% (E(3.82b)/V(3.86b) * Re(8.53%) + (debt cost/tax rate unavailable))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.24%
[DCF Debug] Terminal Value 68.29% ; FCFE base≈199.7m ; Y1≈131.1m ; Y5≈60.0m
Fair Price DCF = 6.42 (DCF Value 1.09b / Shares Outstanding 169.2m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 69.42 | EPS CAGR: 81.76% | SUE: 1.27 | # QB: 1
Revenue Correlation: 88.17 | Revenue CAGR: 29.63% | SUE: 0.22 | # QB: 0

Additional Sources for ACAD Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle